Korro Bio, Inc. (KRRO) Investor Relations Documents

Korro Bio, Inc. (KRRO) investor relations documents from the company's IR site: 4 presentations, 33 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

Korro Bio August 2026 Corporate Presentation: Korro Bio’s August 2026 corporate presentation highlights its RNA editing platform, with KRRO-121 regulatory approval for hyperammonemia expected in H2 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14Press releasePDF Version
2026-08-14Press releaseKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-06Press releaseKorro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-05PresentationKorro Bio August 2026 Corporate Presentation
2026-07-10Press releaseKorro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-08PresentationPDF Version
2026-05-27Press releaseKorro to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-19Press releaseKorro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
2026-05-15Press releaseKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07PresentationKorro Bio American Society of Gene and Cell Therapy 2026 TDP43 Poster
2026-05-07Press releaseKorro Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-05Press releaseKorro to Participate in Upcoming Investor Conferences
2026-04-16Press releaseKorro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
2026-04-10Press releaseKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-03-12Press releaseKorro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-02-25Press releaseKorro to Present at the TD Cowen 46th Annual Health Care Conference
2026-01-27PresentationAnalyst Day Presentation
2026-01-20Press releaseKorro to Host Virtual Analyst Day on January 27, 2026
2026-01-08Press releaseKorro to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-09-02Press releaseKorro to Participate in Upcoming Investor and Scientific Conferences
Press releaseKorro Reports Second Quarter 2025 Financial Results and Provides Business Updates
2025-07-21Press releaseKorro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
2025-05-14Press releaseKorro to Participate in Upcoming Investor Conferences
Press releaseKorro Reports First Quarter 2025 Financial Results and Provides Business Updates
2025-03-18Press releasePDF Version
2025-03-18Press releaseKorro Reports Full Year 2024 Financial Results and Provides Business Updates
2025-03-14Press releasePDF Version
2025-03-14Press releaseKRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
2025-02-26Press releasePDF Version
2025-02-26Press releaseKorro to Present at the TD Cowen 45th Annual Health Care Conference
2024-11-12Press releaseKorro Reports Third Quarter 2024 Financial Results and Provides Business Updates
2024-08-13Press releaseKorro Reports Second Quarter 2024 Financial Results and Provides Business Updates
2024-05-14Press releaseKorro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
2024-03-26Press releaseKorro Reports Full Year 2023 Financial Results and Highlights Recent Progress
2024-01-04Press releasePDF Version
2023-03-07Press releasePDF Version
2022-06-06Press releasePDF Version

KRRO overview · KRRO earnings · KRRO financials · KRRO KPIs · KRRO ownership · KRRO peers · KRRO filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.